What is venture philanthropy?

EBRP's Venture Philanthropy model leverages concepts from principal investing and applies them towards achieving philanthropic goals. When making a grant to a research project, we retain the added upside of generating a recurring donation stream if the therapy or product is commercially successful. That revenue then goes back into funding additional EB research, giving your donation the potential to grow to multiples of its original value.

​Historically, non-profits have passed on these financial benefits. Instead, EBRP participates in them, making philanthropy sustainable. Through partnerships with the University of Minnesota and Stanford University, EBRP pioneered the venture agreements that we use for all grantmaking.

Learn More

To realize our vision of a world without EB, we're building a model based on three core pillars: Share, Collaborate, Cure. Learn more about our Venture Into Cures methodology to accelerate the path to EB therapies.

Read Campaign Prospectus

Global Genes covers our model from Venture Philanthopy, to strategic partnerships, and our vision for a first-of-its kind data platform to advance treatments and cures for EB in this case study.

Read Case Study

industry leadership

---

Patient-driven foundations are focused on the asset that can’t be replaced—time. " The Milken Institute's FasterCures took a deep dive into our  Venture Philanthropy model in The Research Acceleration and Innovation Network (TRAIN) webinar series. The discussion focuses on the formation of Wings Therapeutics, facilitated by EBRP, to take over development of ProQR Therapeutics' EB therapy. 

Read Case Study

---

Harvard Business School's Kraft Precision Medicine Accelerator focuses on advancing therapies for patients by employing modern business plans that keep up with cutting-edge science. As a member, we advise the group on Venture Philanthropy. In "Innovative Funding Models to Drive Cures," the group highlights EBRP as a leader in the space making progress toward cures by focusing on sustainable philanthropy.

Read Full Text

in the press

Read More

AUGUST 13, 2020
​"Just because you're a nonprofit doesn't mean you can't act like a business" says EBRP CEO Michael Hund in USA Today. As a member of Harvard Business School's Kraft Precision Medicine Accelerator, a program that offers guidance to medical nonprofits in search of cures, he advises the group on navigating venture philanthropy. Although COVID-19 has posed unique challenges to the medical research community, EBRP has forged ahead to advance therapies for EB.